1. Evaluate patient-specific factors related to the diagnosis of hypertension.

2. Analyze clinical practice guidelines and primary literature that affect current hypertension management strategies.

3. Develop an individualized hypertension treatment plan using a comprehensive approach.

4. Apply treatment strategies for patients with critical or difficult-to-treat hypertension.

1. Demonstrate the relevance of lipid management in atherosclerotic cardiovascular disease (ASCVD) prevention.

2. Develop a contemporary approach to patient assessment for ASCVD risk, including the roles of risk-enhancing patient characteristics, coronary artery calcium (CAC) and updated lipoprotein targets, and social determinants of health.

3. Analyze emerging recommendations for absolute risk assessment of ASCVD on the basis of cardiovascular-kidney-metabolic syndromes, including the sex-specific, race-free AHA Predicting Risk of CVD Events (PREVENT) model.

4. Develop a pharmacologic treatment plan for dyslipidemia emphasizing a variety of patient subsets and situations requiring statin and non-statin therapies for low-density lipoprotein cholesterol (LDL-C) lowering.

5. Evaluate the pharmacist’s role in complex lipid management, including evidence-based strategies for collaborative practice and deploying higher-cost medications.

1. Account for the effect of lifestyle decisions on the morbidity and mortality of cardiovascular disease.

2. Identify challenges that may impede a patient’s success in lifestyle changes.

3. Distinguish characteristics of health behavior theories.

4. Apply behavioral approaches to implement lifestyle modifications to a patient case.

5. Evaluate the role of technology in providing additional support for patients making lifestyle modifications.

1. Distinguish heart failure with preserved ejection fraction (HFpEF) from other forms of HF, including HF with reduced EF (HFrEF), HF with improved EF (HFimpEF), and HF with mildly reduced EF (HFmrEF).

2. Evaluate the roles of sodium-glucose cotransporter-2 (SGLT2) inhibitors, mineralocorticoid receptor antagonists (MRAs), and angiotensin receptor-neprilysin inhibitor (ARNI) in the management of HFpEF.

3. Develop a pharmacologic treatment plan for managing HFpEF using guideline-directed medical therapy (GDMT).

4. Design a therapeutic plan to manage the common comorbidities encountered in patients with HFpEF.

5. Evaluate patients for referral to general cardiology or an HF specialist.

1. Identify the optimal approach to treatment decisions as patients transition to the ambulatory care environment after an ACS event, including addressing challenges, team- based care, and social determinants of health.

2. Determine key guideline recommendations for the management of patients following an ACS event for optimization of cardiovascular risk lowering therapy in the ambulatory care environment.

3. Evaluate available literature describing current controversies in cardiovascular risk lowering therapy following an ACS event, such as duration and optimization of combination antiplatelet therapy with anticoagulation.

4. Develop a pharmacologic treatment plan for managing a patient post ACS emphasizing cardiovascular risk lowering therapy based on special patient populations and guideline directed care.

5. Evaluate the pharmacist’s role in the process of transitioning care to the ambulatory care environment following an ACS event, including evidence-based strategies for collaborative practice and deploying higher-cost medications.

1. Distinguish the pathophysiology and classifications of orthostatic hypotension (OH).

2. Assess patients for modifiable risk factors associated with the development and precipitation of OH.

3. Develop appropriate nonpharmacologic and pharmacologic treatment plans for the management of OH.

4. Evaluate concurrent health conditions that may affect therapeutic approaches for patients with OH.

5. Design evidence-based therapy for patients with OH using recent and relevant clinical practice guidelines.

1. Compare and contrast available models used to evaluate venous thromboembolism (VTE) risk in various patient populations

2. Design appropriate thromboprophylaxis regimens for at-risk patients, including special populations

3. Assess available evidence and current guideline recommendations focused on thromboprophylaxis

4. Develop strategies to incorporate antithrombosis stewardship principles into thromboprophylaxis practices

1. Analyze the associated thrombotic risks associated with valvular heart disease (VHD) repair and replacement options.

2. Develop a pharmacologic treatment plan for a variety of patient subsets and situations after VHD correction surgery that optimizes the use of guideline-directed medical therapy.

3. Identify the pharmacist’s role in anticoagulation stewardship in patients with VHD.

1. Justify the pharmacist’s role in interpreting ECG.  

2. Evaluate and interpret normal and abnormal waveforms and intervals on an ECG.

3. Measure and calculate the QT/QTc interval using a 12-lead ECG.

4. Given a patient case and 12-lead ECG, analyze factors that influence the accuracy and reliability of the heart rate corrected QT interval (QTc).

5. Given a patient case, analyze risk factors for QT prolongation.

6. Given a patient case, provide recommendations for the management of QT prolongation.